Table 1 Patient characteristics
From: Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
N (%) | |
|---|---|
Gender | |
Male | 48 (60.8) |
Female | 31 (39.2) |
Age | |
Median (range) | 51 (0–73) |
Underlying disease | |
Acute myeloblastic leukemia | 30 (38) |
Acute lymphoblastic leukemia | 12 (15.2) |
Myelodysplastic syndrome | 11 (13.9) |
Multiple myeloma | 3 (3.8) |
Hodgkin disease | 2 (2.5) |
Non-Hodgkin disease | 13 (16.5) |
Myelofibrosis | 4 (5.1) |
Others | 4 (5.1) |
Disease status previous HSCT | |
CR | 47 (59.5) |
PR | 13 (16.5) |
SD | 11 (13.9) |
Others | 8 (10,1) |
Type of transplant | |
Related HLA identical donor | 33 (41.7) |
Haploidentical | 7 (8.8) |
Unrelated donor | 39 (49.3) |
Conditioning regimen | |
Myeloablative | 34 (43) |
Reduced-intensity | 45 (57) |
Source | |
Peripheral blood | 75 (95) |
Bone marrow | 2 (2.5) |
Umbilical cord | 2 (2.5) |
Acute GVHD (n = 23) | N (%) |
|---|---|
Grades | |
2–4 | 23 (100) |
3–4 | 20 (87) |
Organs involved | |
Skin | 16 (69.6) |
Gut | 21 (95.5) |
Liver | 13 (59.1) |
Previous lines of therapy | |
1 | 4 (18.2) |
2 | 7 (31.8) |
3 | 6 (26.1) |
>3 | 6 (27.2) |
Chronic GVHD (n = 56) | N (%) |
|---|---|
NIH score | |
Mild | 0 (0) |
Moderate | 28 (50) |
Severe | 28 (50) |
Organs involved | |
Skin | 44 (78.5) |
Sclerotic changes | 25 (41.1) |
Resembling lichen planus | 2 (3.6) |
Rash | 13 (23.2) |
Hyper/hypopigmentation | 3 (5.4) |
Ichthyosis | 3 (5.4) |
Oral | 33 (58.9) |
Ocular | 23 (41) |
Gut | 16 (28.6) |
Liver | 10 (17.8) |
Lung | 26 (45) |
Joint mobility disfunction | 22 (39.4) |
Urinary tract | 7 (12.5) |
Esophageal membrane | 2 (3.6) |
Pericardial/pleural effusion | 2 (3.6) |
Nephrotic syndrome | 1 (1.8) |
Neuropathy | 1 (1.8) |
Microangiopathy | 1 (1.8) |
Polymyositis | 3 (5.3) |
Previous lines of therapy | |
1 | 4 (7.1) |
2 | 20 (35.7) |
3 | 11 (19.6) |
>3 | 21 (37.6) |
